Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?  

I can think of two ways to answer this question. First, the FDA indication for elacestrant follows the design of the phase III EMERALD trial (Bidard et al., PMID 35584336). The EMERALD trial permitted patients with prior disease progression on one or two prior lines of endocrine therapy (up to 1 lin...